Drugs For Non-Small Cell Lung Cancer Market Report

China Drugs For Non-Small Cell Lung Cancer Industry Market Research Report 2023-2029

  • POSTDATE：Oct 15, 2023
  • PAGES：233
  • REPORT CODE：GMM1857507
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • This report elaborates on the current development of the Drugs For Non-Small Cell Lung Cancer industry thoroughly based on the international market dynamics and China's market situation.

    For a start, the report provides an in-depth analysis of the current market situation through three different aspects - by region, by type and by application, which includes market distribution of different types and applications, import and export analysis of major regions, development trends of different types of products in each region, market opportunities and market restrains of different applications.

    Secondly, this report lists the major players in the industry, displaying their market positions and strengths and weaknesses of their products, picturing the current competitive situation of the whole market. 

    Last but not least, the report analyzes and predicts the investment prospects and risks in the industry on the basis of industry data, combined with experts' opinions and suggestions.

    By Player:

    • Menarini

    • Kyowa Hakko Kirin

    • Hikma Pharmaceuticals

    • Exelixis

    • Curis

    • Bristol-Myers Squibb

    • Cornerstone Pharmaceuticals

    • CellAct Pharma

    • Fresenius Kabi

    • Amgen

    • Genentech

    • Intas Pharmaceuticals

    • GlaxoSmithKline

    • Eli Lilly

    • Karyopharm Therapeutics

    • BioMarin Pharmaceutical

    • Sanofi

    • ZIOPHARM Oncology

    • Alchemia

    • Apotex

    • Cerulean Pharma

    • Hospira

    By Type:

    • Chemotherapy

    • Targeted therapies

    • Surgery

    • Radiofrequency ablation (RFA)

    • Radiation therapy

    • Immunotherapy

    By Application:

    • Application 1

    • Application 2

    • Application 3

    By Research Region:

    • North China

    • Central China

    • South China

    • East China

    • Northeast China

    • Southwest China

    • Northwest China

  • TABLE OF CONTENT

    Chapter 1 China Drugs For Non-Small Cell Lung Cancer Market Overview 2018-2029

    • 1.1 China Drugs For Non-Small Cell Lung Cancer Industry Development Overview

    • 1.2 China Drugs For Non-Small Cell Lung Cancer Industry Development History

    • 1.3 China Drugs For Non-Small Cell Lung Cancer Industry Market Size (2018-2029)

    • 1.4 China Drugs For Non-Small Cell Lung Cancer Market Analysis by Type from Production Side

      • 1.4.1 China Drugs For Non-Small Cell Lung Cancer Production Volume, Production Value and Growth Rate of Chemotherapy (2018-2029)

      • 1.4.2 China Drugs For Non-Small Cell Lung Cancer Production Volume, Production Value and Growth Rate of Targeted therapies (2018-2029)

      • 1.4.3 China Drugs For Non-Small Cell Lung Cancer Production Volume, Production Value and Growth Rate of Surgery (2018-2029)

      • 1.4.4 China Drugs For Non-Small Cell Lung Cancer Production Volume, Production Value and Growth Rate of Radiofrequency ablation (RFA) (2018-2029)

      • 1.4.5 China Drugs For Non-Small Cell Lung Cancer Production Volume, Production Value and Growth Rate of Radiation therapy (2018-2029)

      • 1.4.6 China Drugs For Non-Small Cell Lung Cancer Production Volume, Production Value and Growth Rate of Immunotherapy (2018-2029)

    • 1.5 China Drugs For Non-Small Cell Lung Cancer Market Analysis by Application from Consumption End

      • 1.5.1 China Drugs For Non-Small Cell Lung Cancer Sales Volume, Sales Value and Growth Rate of Application 1 (2018-2029)

      • 1.5.2 China Drugs For Non-Small Cell Lung Cancer Sales Volume, Sales Value and Growth Rate of Application 2 (2018-2029)

      • 1.5.3 China Drugs For Non-Small Cell Lung Cancer Sales Volume, Sales Value and Growth Rate of Application 3 (2018-2029)

    • 1.6 China Drugs For Non-Small Cell Lung Cancer Market Analysis by Region

      • 1.6.1 North China Drugs For Non-Small Cell Lung Cancer Market Size and Growth Rate from 2018-2029

      • 1.6.2 Central China Drugs For Non-Small Cell Lung Cancer Market Size and Growth Rate from 2018-2029

      • 1.6.3 South China Drugs For Non-Small Cell Lung Cancer Market Size and Growth Rate from 2018-2029

      • 1.6.4 East China Drugs For Non-Small Cell Lung Cancer Market Size and Growth Rate from 2018-2029

      • 1.6.5 Northeast China Drugs For Non-Small Cell Lung Cancer Market Size and Growth Rate from 2018-2029

      • 1.6.6 Southwest China Drugs For Non-Small Cell Lung Cancer Market Size and Growth Rate from 2018-2029

      • 1.6.7 Northwest China Drugs For Non-Small Cell Lung Cancer Market Size and Growth Rate from 2018-2029

    Chapter 2 China Drugs For Non-Small Cell Lung Cancer Industry Development Environment

    • 2.1 Industry Development Environment Analysis

      • 2.1.1 Industry Technological Progress Analysis

      • 2.1.2 Industrial Organizational Innovation Analysis

      • 2.1.3 Changes in Social Habits

      • 2.1.4 Alterations in Government Policies

      • 2.1.5 Impact of Economic Globalization

    • 2.2 Domestic and Foreign Industry Competition Analysis

      • 2.2.1 Comparative Analysis on Drugs For Non-Small Cell Lung Cancer Market Status and Competition at home and abroad in 2023

      • 2.2.2 China Drugs For Non-Small Cell Lung Cancer Market Status and Competition Analysis in 2023

      • 2.2.3 China Drugs For Non-Small Cell Lung Cancer Market Concentration Analysis in 2023

    • 2.3 Problems and Countermeasures in the development of China Drugs For Non-Small Cell Lung Cancer Industry

      • 2.3.1 Industry Development Constraints

      • 2.3.2 Industry Development Considerations

      • 2.3.3 Suggestions on Industry Development Measures

      • 2.3.4 Development Strategies for SMEs

    • 2.4 Influence of COVID-19 Outbreak on Drugs For Non-Small Cell Lung Cancer Industry Development

    Chapter 3 Drugs For Non-Small Cell Lung CancerIndustry Chain Analysis

    • 3.1 Drugs For Non-Small Cell Lung Cancer Industry Chain

    • 3.2 Drugs For Non-Small Cell Lung Cancer Upstream Industry Analysis

      • 3.2.1 Upstream Industry Development Status

      • 3.2.2 Upstream Industry Development Forecast

      • 3.2.3 Impact of Upstream Industry on the Drugs For Non-Small Cell Lung Cancer Market

    • 3.3 Drugs For Non-Small Cell Lung Cancer Downstream Industry Analysis

      • 3.3.1 Downstream Industry Development Status

      • 3.3.2 Downstream Industry Development Forecast

      • 3.3.3 Impact of Downstream Industry on the Drugs For Non-Small Cell Lung Cancer Market

    Chapter 4 China Drugs For Non-Small Cell Lung Cancer Market, by Type

    • 4.1 China Drugs For Non-Small Cell Lung Cancer Market Trend, by Type

    • 4.2 Product Types of Major Suppliers

    • 4.3 Competitive Landscape of Major Types

    • 4.4 China Drugs For Non-Small Cell Lung Cancer Total Production Volume and Growth Rate from Production Side

    • 4.5 China Drugs For Non-Small Cell Lung Cancer Production Volume and Growth Rate, by Type

      • 4.5.1 China Drugs For Non-Small Cell Lung Cancer Production Volume and Growth Rate of Chemotherapy

      • 4.5.2 China Drugs For Non-Small Cell Lung Cancer Production Volume and Growth Rate of Targeted therapies

      • 4.5.3 China Drugs For Non-Small Cell Lung Cancer Production Volume and Growth Rate of Surgery

      • 4.5.4 China Drugs For Non-Small Cell Lung Cancer Production Volume and Growth Rate of Radiofrequency ablation (RFA)

      • 4.5.5 China Drugs For Non-Small Cell Lung Cancer Production Volume and Growth Rate of Radiation therapy

      • 4.5.6 China Drugs For Non-Small Cell Lung Cancer Production Volume and Growth Rate of Immunotherapy

    Chapter 5 China Drugs For Non-Small Cell Lung Cancer Market, by Application

    • 5.1 Downstream Market Overview

    • 5.2 Competitive Landscape of Major Applications

    • 5.3 Market Potential Analysis, by Application

    • 5.4 China Drugs For Non-Small Cell Lung Cancer Total Market Size and Growth Rate from Consumption End

    • 5.5 China Drugs For Non-Small Cell Lung Cancer Market Size and Growth Rate, by Application

      • 5.5.1 China Drugs For Non-Small Cell Lung Cancer Market Size and Growth Rate of Application 1

      • 5.5.2 China Drugs For Non-Small Cell Lung Cancer Market Size and Growth Rate of Application 2

      • 5.5.3 China Drugs For Non-Small Cell Lung Cancer Market Size and Growth Rate of Application 3

    Chapter 6 China Drugs For Non-Small Cell Lung Cancer Market, by Region

    • 6.1 China Drugs For Non-Small Cell Lung Cancer Production Volume and Production Value, by Region

    • 6.2 China Drugs For Non-Small Cell Lung Cancer Sales Volume and Sales Value, by Region

    Chapter 7 North China Drugs For Non-Small Cell Lung Cancer Market Analysis

    • 7.1 North China Drugs For Non-Small Cell Lung Cancer Market, by Type

    • 7.2 North China Drugs For Non-Small Cell Lung Cancer Market, by Application

    Chapter 8 Central China Drugs For Non-Small Cell Lung Cancer Market Analysis

    • 8.1 Central China Drugs For Non-Small Cell Lung Cancer Market, by Type

    • 8.2 Central China Drugs For Non-Small Cell Lung Cancer Market, by Application

    Chapter 9 South China Drugs For Non-Small Cell Lung Cancer Market Analysis

    • 9.1 South China Drugs For Non-Small Cell Lung Cancer Market, by Type

    • 9.2 South China Drugs For Non-Small Cell Lung Cancer Market, by Application

    Chapter 10 East China Drugs For Non-Small Cell Lung Cancer Market Analysis

    • 10.1 East China Drugs For Non-Small Cell Lung Cancer Market, by Type

    • 10.2 East China Drugs For Non-Small Cell Lung Cancer Market, by Application

    Chapter 11 Northeast China Drugs For Non-Small Cell Lung Cancer Market Analysis

    • 11.1 Northeast China Drugs For Non-Small Cell Lung Cancer Market, by Type

    • 11.2 Northeast China Drugs For Non-Small Cell Lung Cancer Market, by Application

    Chapter 12 Southwest China Drugs For Non-Small Cell Lung Cancer Market Analysis

    • 12.1 Southwest China Drugs For Non-Small Cell Lung Cancer Market, by Type

    • 12.2 Southwest China Drugs For Non-Small Cell Lung Cancer Market, by Application

    Chapter 13 Northwest China Drugs For Non-Small Cell Lung Cancer Market Analysis

    • 13.1 Northwest China Drugs For Non-Small Cell Lung Cancer Market, by Type

    • 13.2 Northwest China Drugs For Non-Small Cell Lung Cancer Market, by Application

    Chapter 14 Company Profiles

      • 14.1 Menarini

        • 14.1.1 Menarini Company Profile

        • 14.1.2 Menarini Drugs For Non-Small Cell Lung Cancer Market Performance

        • 14.1.3 Product&Service Introduction

      • 14.2 Kyowa Hakko Kirin

        • 14.2.1 Kyowa Hakko Kirin Company Profile

        • 14.2.2 Kyowa Hakko Kirin Drugs For Non-Small Cell Lung Cancer Market Performance

        • 14.2.3 Product&Service Introduction

      • 14.3 Hikma Pharmaceuticals

        • 14.3.1 Hikma Pharmaceuticals Company Profile

        • 14.3.2 Hikma Pharmaceuticals Drugs For Non-Small Cell Lung Cancer Market Performance

        • 14.3.3 Product&Service Introduction

      • 14.4 Exelixis

        • 14.4.1 Exelixis Company Profile

        • 14.4.2 Exelixis Drugs For Non-Small Cell Lung Cancer Market Performance

        • 14.4.3 Product&Service Introduction

      • 14.5 Curis

        • 14.5.1 Curis Company Profile

        • 14.5.2 Curis Drugs For Non-Small Cell Lung Cancer Market Performance

        • 14.5.3 Product&Service Introduction

      • 14.6 Bristol-Myers Squibb

        • 14.6.1 Bristol-Myers Squibb Company Profile

        • 14.6.2 Bristol-Myers Squibb Drugs For Non-Small Cell Lung Cancer Market Performance

        • 14.6.3 Product&Service Introduction

      • 14.7 Cornerstone Pharmaceuticals

        • 14.7.1 Cornerstone Pharmaceuticals Company Profile

        • 14.7.2 Cornerstone Pharmaceuticals Drugs For Non-Small Cell Lung Cancer Market Performance

        • 14.7.3 Product&Service Introduction

      • 14.8 CellAct Pharma

        • 14.8.1 CellAct Pharma Company Profile

        • 14.8.2 CellAct Pharma Drugs For Non-Small Cell Lung Cancer Market Performance

        • 14.8.3 Product&Service Introduction

      • 14.9 Fresenius Kabi

        • 14.9.1 Fresenius Kabi Company Profile

        • 14.9.2 Fresenius Kabi Drugs For Non-Small Cell Lung Cancer Market Performance

        • 14.9.3 Product&Service Introduction

      • 14.10 Amgen

        • 14.10.1 Amgen Company Profile

        • 14.10.2 Amgen Drugs For Non-Small Cell Lung Cancer Market Performance

        • 14.10.3 Product&Service Introduction

      • 14.11 Genentech

        • 14.11.1 Genentech Company Profile

        • 14.11.2 Genentech Drugs For Non-Small Cell Lung Cancer Market Performance

        • 14.11.3 Product&Service Introduction

      • 14.12 Intas Pharmaceuticals

        • 14.12.1 Intas Pharmaceuticals Company Profile

        • 14.12.2 Intas Pharmaceuticals Drugs For Non-Small Cell Lung Cancer Market Performance

        • 14.12.3 Product&Service Introduction

      • 14.13 GlaxoSmithKline

        • 14.13.1 GlaxoSmithKline Company Profile

        • 14.13.2 GlaxoSmithKline Drugs For Non-Small Cell Lung Cancer Market Performance

        • 14.13.3 Product&Service Introduction

      • 14.14 Eli Lilly

        • 14.14.1 Eli Lilly Company Profile

        • 14.14.2 Eli Lilly Drugs For Non-Small Cell Lung Cancer Market Performance

        • 14.14.3 Product&Service Introduction

      • 14.15 Karyopharm Therapeutics

        • 14.15.1 Karyopharm Therapeutics Company Profile

        • 14.15.2 Karyopharm Therapeutics Drugs For Non-Small Cell Lung Cancer Market Performance

        • 14.15.3 Product&Service Introduction

      • 14.16 BioMarin Pharmaceutical

        • 14.16.1 BioMarin Pharmaceutical Company Profile

        • 14.16.2 BioMarin Pharmaceutical Drugs For Non-Small Cell Lung Cancer Market Performance

        • 14.16.3 Product&Service Introduction

      • 14.17 Sanofi

        • 14.17.1 Sanofi Company Profile

        • 14.17.2 Sanofi Drugs For Non-Small Cell Lung Cancer Market Performance

        • 14.17.3 Product&Service Introduction

      • 14.18 ZIOPHARM Oncology

        • 14.18.1 ZIOPHARM Oncology Company Profile

        • 14.18.2 ZIOPHARM Oncology Drugs For Non-Small Cell Lung Cancer Market Performance

        • 14.18.3 Product&Service Introduction

      • 14.19 Alchemia

        • 14.19.1 Alchemia Company Profile

        • 14.19.2 Alchemia Drugs For Non-Small Cell Lung Cancer Market Performance

        • 14.19.3 Product&Service Introduction

      • 14.20 Apotex

        • 14.20.1 Apotex Company Profile

        • 14.20.2 Apotex Drugs For Non-Small Cell Lung Cancer Market Performance

        • 14.20.3 Product&Service Introduction

      • 14.21 Cerulean Pharma

        • 14.21.1 Cerulean Pharma Company Profile

        • 14.21.2 Cerulean Pharma Drugs For Non-Small Cell Lung Cancer Market Performance

        • 14.21.3 Product&Service Introduction

      • 14.22 Hospira

        • 14.22.1 Hospira Company Profile

        • 14.22.2 Hospira Drugs For Non-Small Cell Lung Cancer Market Performance

        • 14.22.3 Product&Service Introduction

    Chapter 15 Research Conclusions and Investment Suggestions

    • 15.1 Drugs For Non-Small Cell Lung Cancer Industry Research Conclusions

    • 15.2 Drugs For Non-Small Cell Lung Cancer Industry Investment Suggestions

      • 15.2.1 Suggestions on Industry Development Strategy

      • 15.2.2 Suggestions on Industry Investment Direction

      • 15.2.3 Suggestions on Industry Investment Strategy


    List of Tables and Figures

    • Figure China Drugs For Non-Small Cell Lung Cancer Industry Market Size (2018-2029)

    • Figure China Drugs For Non-Small Cell Lung Cancer Production Volume, Production Value and Growth Rate of Chemotherapy (2018-2029)

    • Figure China Drugs For Non-Small Cell Lung Cancer Production Volume, Production Value and Growth Rate of Targeted therapies (2018-2029)

    • Figure China Drugs For Non-Small Cell Lung Cancer Production Volume, Production Value and Growth Rate of Surgery (2018-2029)

    • Figure China Drugs For Non-Small Cell Lung Cancer Production Volume, Production Value and Growth Rate of Radiofrequency ablation (RFA) (2018-2029)

    • Figure China Drugs For Non-Small Cell Lung Cancer Production Volume, Production Value and Growth Rate of Radiation therapy (2018-2029)

    • Figure China Drugs For Non-Small Cell Lung Cancer Production Volume, Production Value and Growth Rate of Immunotherapy (2018-2029)

    • Figure China Drugs For Non-Small Cell Lung Cancer Sales Volume, Sales Value and Growth Rate of Application 1 (2018-2029)

    • Figure China Drugs For Non-Small Cell Lung Cancer Sales Volume, Sales Value and Growth Rate of Application 2 (2018-2029)

    • Figure China Drugs For Non-Small Cell Lung Cancer Sales Volume, Sales Value and Growth Rate of Application 3 (2018-2029)

    • Figure North China Drugs For Non-Small Cell Lung Cancer Market Size and Growth Rate from 2018-2029

    • Figure Central China Drugs For Non-Small Cell Lung Cancer Market Size and Growth Rate from 2018-2029

    • Figure South China Drugs For Non-Small Cell Lung Cancer Market Size and Growth Rate from 2018-2029

    • Figure East China Drugs For Non-Small Cell Lung Cancer Market Size and Growth Rate from 2018-2029

    • Figure Northeast China Drugs For Non-Small Cell Lung Cancer Market Size and Growth Rate from 2018-2029

    • Figure Southwest China Drugs For Non-Small Cell Lung Cancer Market Size and Growth Rate from 2018-2029

    • Figure Northwest China Drugs For Non-Small Cell Lung Cancer Market Size and Growth Rate from 2018-2029

    • Figure Drugs For Non-Small Cell Lung Cancer Industry Chain

    • Table Product Types of Major Suppliers in 2023

    • Figure China Drugs For Non-Small Cell Lung Cancer Market Share by Type in 2018

    • Figure China Drugs For Non-Small Cell Lung Cancer Market Share by Type in 2023

    • Figure China Drugs For Non-Small Cell Lung Cancer Total Production Volume and Growth Rate from Production Side (2018-2023)

    • Figure China Drugs For Non-Small Cell Lung Cancer Production Volume and Growth Rate of Chemotherapy (2018-2023)

    • Figure China Drugs For Non-Small Cell Lung Cancer Production Volume and Growth Rate of Targeted therapies (2018-2023)

    • Figure China Drugs For Non-Small Cell Lung Cancer Production Volume and Growth Rate of Surgery (2018-2023)

    • Figure China Drugs For Non-Small Cell Lung Cancer Production Volume and Growth Rate of Radiofrequency ablation (RFA) (2018-2023)

    • Figure China Drugs For Non-Small Cell Lung Cancer Production Volume and Growth Rate of Radiation therapy (2018-2023)

    • Figure China Drugs For Non-Small Cell Lung Cancer Production Volume and Growth Rate of Immunotherapy (2018-2023)

    • Figure China Drugs For Non-Small Cell Lung Cancer Market Share by Application in 2018

    • Figure China Drugs For Non-Small Cell Lung Cancer Market Share by Application in 2023

    • Figure China Drugs For Non-Small Cell Lung Cancer Total Market Size and Growth Rate from Consumption End

    • Figure China Drugs For Non-Small Cell Lung Cancer Market Size and Growth Rate of Application 1 (2018-2023)

    • Figure China Drugs For Non-Small Cell Lung Cancer Market Size and Growth Rate of Application 2 (2018-2023)

    • Figure China Drugs For Non-Small Cell Lung Cancer Market Size and Growth Rate of Application 3 (2018-2023)

    • Table China Drugs For Non-Small Cell Lung Cancer Production Volume by Region (2018-2023)

    • Table China Drugs For Non-Small Cell Lung Cancer Production Volume Share by Region (2018-2023)

    • Figure China Drugs For Non-Small Cell Lung Cancer Production Volume Share by Region (2018-2023)

    • Table China Drugs For Non-Small Cell Lung Cancer Production Value by Region (2018-2023)

    • Table China Drugs For Non-Small Cell Lung Cancer Production Value Share by Region (2018-2023)

    • Figure China Drugs For Non-Small Cell Lung Cancer Production Value Share by Region (2018-2023)

    • Table China Drugs For Non-Small Cell Lung Cancer Sales Volume by Region (2018-2023)

    • Table China Drugs For Non-Small Cell Lung Cancer Sales Volume Share by Region (2018-2023)

    • Figure China Drugs For Non-Small Cell Lung Cancer Sales Volume Share by Region (2018-2023)

    • Table China Drugs For Non-Small Cell Lung Cancer Sales Value by Region (2018-2023)

    • Table China Drugs For Non-Small Cell Lung Cancer Sales Value Share by Region (2018-2023)

    • Figure China Drugs For Non-Small Cell Lung Cancer Sales Value Share by Region (2018-2023)

    • Table North China Drugs For Non-Small Cell Lung Cancer Production Volume by Type (2018-2023)

    • Table North China Drugs For Non-Small Cell Lung Cancer Production Volume Share by Type (2018-2023)

    • Figure North China Drugs For Non-Small Cell Lung Cancer Production Volume Share by Type (2018-2023)

    • Table North China Drugs For Non-Small Cell Lung Cancer Sales Volume by Application (2018-2023)

    • Table North China Drugs For Non-Small Cell Lung Cancer Sales Volume Share by Application (2018-2023)

    • Figure North China Drugs For Non-Small Cell Lung Cancer Sales Volume Share by Application (2018-2023)

    • Table Central China Drugs For Non-Small Cell Lung Cancer Production Volume by Type (2018-2023)

    • Table Central China Drugs For Non-Small Cell Lung Cancer Production Volume Share by Type (2018-2023)

    • Figure Central China Drugs For Non-Small Cell Lung Cancer Production Volume Share by Type (2018-2023)

    • Table Central China Drugs For Non-Small Cell Lung Cancer Sales Volume by Application (2018-2023)

    • Table Central China Drugs For Non-Small Cell Lung Cancer Sales Volume Share by Application (2018-2023)

    • Figure Central China Drugs For Non-Small Cell Lung Cancer Sales Volume Share by Application (2018-2023)

    • Table South China Drugs For Non-Small Cell Lung Cancer Production Volume by Type (2018-2023)

    • Table South China Drugs For Non-Small Cell Lung Cancer Production Volume Share by Type (2018-2023)

    • Figure South China Drugs For Non-Small Cell Lung Cancer Production Volume Share by Type (2018-2023)

    • Table South China Drugs For Non-Small Cell Lung Cancer Sales Volume by Application (2018-2023)

    • Table South China Drugs For Non-Small Cell Lung Cancer Sales Volume Share by Application (2018-2023)

    • Figure South China Drugs For Non-Small Cell Lung Cancer Sales Volume Share by Application (2018-2023)

    • Table East China Drugs For Non-Small Cell Lung Cancer Production Volume by Type (2018-2023)

    • Table East China Drugs For Non-Small Cell Lung Cancer Production Volume Share by Type (2018-2023)

    • Figure East China Drugs For Non-Small Cell Lung Cancer Production Volume Share by Type (2018-2023)

    • Table East China Drugs For Non-Small Cell Lung Cancer Sales Volume by Application (2018-2023)

    • Table East China Drugs For Non-Small Cell Lung Cancer Sales Volume Share by Application (2018-2023)

    • Figure East China Drugs For Non-Small Cell Lung Cancer Sales Volume Share by Application (2018-2023)

    • Table Northeast China Drugs For Non-Small Cell Lung Cancer Production Volume by Type (2018-2023)

    • Table Northeast China Drugs For Non-Small Cell Lung Cancer Production Volume Share by Type (2018-2023)

    • Figure Northeast China Drugs For Non-Small Cell Lung Cancer Production Volume Share by Type (2018-2023)

    • Table Northeast China Drugs For Non-Small Cell Lung Cancer Sales Volume by Application (2018-2023)

    • Table Northeast China Drugs For Non-Small Cell Lung Cancer Sales Volume Share by Application (2018-2023)

    • Figure Northeast China Drugs For Non-Small Cell Lung Cancer Sales Volume Share by Application (2018-2023)

    • Table Southwest China Drugs For Non-Small Cell Lung Cancer Production Volume by Type (2018-2023)

    • Table Southwest China Drugs For Non-Small Cell Lung Cancer Production Volume Share by Type (2018-2023)

    • Figure Southwest China Drugs For Non-Small Cell Lung Cancer Production Volume Share by Type (2018-2023)

    • Table Southwest China Drugs For Non-Small Cell Lung Cancer Sales Volume by Application (2018-2023)

    • Table Southwest China Drugs For Non-Small Cell Lung Cancer Sales Volume Share by Application (2018-2023)

    • Figure Southwest China Drugs For Non-Small Cell Lung Cancer Sales Volume Share by Application (2018-2023)

    • Table Northwest China Drugs For Non-Small Cell Lung Cancer Production Volume by Type (2018-2023)

    • Table Northwest China Drugs For Non-Small Cell Lung Cancer Production Volume Share by Type (2018-2023)

    • Figure Northwest China Drugs For Non-Small Cell Lung Cancer Production Volume Share by Type (2018-2023)

    • Table Northwest China Drugs For Non-Small Cell Lung Cancer Sales Volume by Application (2018-2023)

    • Table Northwest China Drugs For Non-Small Cell Lung Cancer Sales Volume Share by Application (2018-2023)

    • Figure Northwest China Drugs For Non-Small Cell Lung Cancer Sales Volume Share by Application (2018-2023)

    • Table Menarini Company Profile

    • Table Menarini Drugs For Non-Small Cell Lung Cancer Revenue, Price and Gross (2018-2023)

    • Table Kyowa Hakko Kirin Company Profile

    • Table Kyowa Hakko Kirin Drugs For Non-Small Cell Lung Cancer Revenue, Price and Gross (2018-2023)

    • Table Hikma Pharmaceuticals Company Profile

    • Table Hikma Pharmaceuticals Drugs For Non-Small Cell Lung Cancer Revenue, Price and Gross (2018-2023)

    • Table Exelixis Company Profile

    • Table Exelixis Drugs For Non-Small Cell Lung Cancer Revenue, Price and Gross (2018-2023)

    • Table Curis Company Profile

    • Table Curis Drugs For Non-Small Cell Lung Cancer Revenue, Price and Gross (2018-2023)

    • Table Bristol-Myers Squibb Company Profile

    • Table Bristol-Myers Squibb Drugs For Non-Small Cell Lung Cancer Revenue, Price and Gross (2018-2023)

    • Table Cornerstone Pharmaceuticals Company Profile

    • Table Cornerstone Pharmaceuticals Drugs For Non-Small Cell Lung Cancer Revenue, Price and Gross (2018-2023)

    • Table CellAct Pharma Company Profile

    • Table CellAct Pharma Drugs For Non-Small Cell Lung Cancer Revenue, Price and Gross (2018-2023)

    • Table Fresenius Kabi Company Profile

    • Table Fresenius Kabi Drugs For Non-Small Cell Lung Cancer Revenue, Price and Gross (2018-2023)

    • Table Amgen Company Profile

    • Table Amgen Drugs For Non-Small Cell Lung Cancer Revenue, Price and Gross (2018-2023)

    • Table Genentech Company Profile

    • Table Genentech Drugs For Non-Small Cell Lung Cancer Revenue, Price and Gross (2018-2023)

    • Table Intas Pharmaceuticals Company Profile

    • Table Intas Pharmaceuticals Drugs For Non-Small Cell Lung Cancer Revenue, Price and Gross (2018-2023)

    • Table GlaxoSmithKline Company Profile

    • Table GlaxoSmithKline Drugs For Non-Small Cell Lung Cancer Revenue, Price and Gross (2018-2023)

    • Table Eli Lilly Company Profile

    • Table Eli Lilly Drugs For Non-Small Cell Lung Cancer Revenue, Price and Gross (2018-2023)

    • Table Karyopharm Therapeutics Company Profile

    • Table Karyopharm Therapeutics Drugs For Non-Small Cell Lung Cancer Revenue, Price and Gross (2018-2023)

    • Table BioMarin Pharmaceutical Company Profile

    • Table BioMarin Pharmaceutical Drugs For Non-Small Cell Lung Cancer Revenue, Price and Gross (2018-2023)

    • Table Sanofi Company Profile

    • Table Sanofi Drugs For Non-Small Cell Lung Cancer Revenue, Price and Gross (2018-2023)

    • Table ZIOPHARM Oncology Company Profile

    • Table ZIOPHARM Oncology Drugs For Non-Small Cell Lung Cancer Revenue, Price and Gross (2018-2023)

    • Table Alchemia Company Profile

    • Table Alchemia Drugs For Non-Small Cell Lung Cancer Revenue, Price and Gross (2018-2023)

    • Table Apotex Company Profile

    • Table Apotex Drugs For Non-Small Cell Lung Cancer Revenue, Price and Gross (2018-2023)

    • Table Cerulean Pharma Company Profile

    • Table Cerulean Pharma Drugs For Non-Small Cell Lung Cancer Revenue, Price and Gross (2018-2023)

    • Table Hospira Company Profile

    • Table Hospira Drugs For Non-Small Cell Lung Cancer Revenue, Price and Gross (2018-2023)


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US